A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully. For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users. “If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said. Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market. “It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.” And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021. For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).

Share:
More In Business
Stretching Your Dollar: What Thanksgiving Food Prices Could Look Like
As the holiday season nears and with families making plans for Thanksgiving at the end of the month, concerns about high food prices linger. Dr. Michael Swanson, chief agricultural economist with Wells Fargo Agri-Food Institute, joined Cheddar News to provide tips on what to expect when shopping for those large family meals.
Load More